February 13, 2025 Customer Newsletter
- Working More and Getting Less
- Ready for the ABFM Boards?
- Direct-to-Consumer Advertising
- PEMQBook Live Board Review
- AMA Meets Need for New CPT Codes
- QUIZ - Test Your Knowledge
Physicians Working More but Generating Less Revenue
OK, we’re sorry, but this entire article reads like some sort of horrible dystopian fiction. The focus—being a CFO-type article—is on physicians working 8% more, and some getting paid 8% more (a rather uneven break), with fewer staff.
The conclusion drawn from the fact that you can’t keep pushing physicians to generate more and more RVUs and expand margins is that the fee-for-service model has failed. Therefore, we have to stop paying physicians fee-for-service and create an even more complex payment system.
Excuse us while we freak out. 🤢
Physicians Working More but Generating Less Revenue - Becker’s Hospital CFO Report
Prescription advertising is about to become a political football in the United States—Super Bowl reference intended. In this case, the AAFP is highlighting the actual cost ($288,000) of a drug advertised during the Super Bowl, compared to the promoted price (as low as $5 per dose). This pricing discrepancy is made possible through the deductible rebate card program. It’s not an outright lie—the patient’s out-of-pocket cost after the rebate is indeed $0 to $5 per dose, but only if the insurer covers it. The negotiated rate with Medicare, however, is a different story. As the AAFP points out, this is not a drug a physician would typically prescribe today for even serious plaque psoriasis. While it is an effective medication, it is generally reserved for patients who have not responded to more affordable alternatives or have encountered issues with anti-TNF therapies. Direct-to-consumer (DTC) prescription advertising first appeared in the 1980s but didn’t gain traction until 1997, when the FDA clarified how risk and benefit information should be presented—often alongside glowing, happy images of elderly patients. Given some of the more extreme examples and the rise of DTC telehealth from the same pharmaceutical companies, pushback is growing. Direct-to-Consumer Advertising Distorts Prescription Drugs’ Benefits and Costs - AAFP
|